Current and future directions for adjuvant chemotherapy in early-stage breast cancer

European Journal of Cancer, Supplement

Volumn 4, Issue 4, 2006, Pages 14-20

  Ellis, Paul ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Adjuvant; Docetaxel; Future; Growth factor; Taxoid

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TAXOID; TRASTUZUMAB;

ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FOLLOW UP; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HEMATOLOGIC DISEASE; HUMAN; MYALGIA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RECURRENCE RISK; STATISTICAL SIGNIFICANCE; STOMATITIS; TREATMENT OUTCOME;

EID: 33646184577     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(06)80004-2     Document Type: Article

References (18)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 9472 (2005) 1687-1717
2. Henderson I., Berry D., Demetri G., et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21 6 (2003) 976-983
3. Mamounas E., bryant J., Lembersky B., et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23 16 (2005) 3686-3696
4. Roché H, Fumoleau P, Spielmann M, et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. In: SAB CS 2004; 2004, Abstr. 27.
5. Martin M., Pienkowski T., Mackey J., et al. Adjuvant docetaxel for nodepositive breast cancer. N Engl J Med 352 22 (2005) 2302-2313
6. Martin M, Ruiz A, Alba E, et al. Multicenter, randomized phaseIII study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FE90 C versus 4 cycles of FE90C followed by 8 weekly paclitaxed administrations: interim efficacy analysis of GEICAM 9906 Trial. In: SABCS 2005: 2005, Abstr. 39.
7. Jones SE, Holmes FA, O'Shaughnessy JA, et al. Final analysis: TC(docetaxel/cyclophosphamide, 4 cycles) has a superior disease-free survival compared to standard AC (doxorubicin/cyclophosphamide) in 1016 women with early stage breast cancer. In: SAB CS 2005; 2005. Abstr. 40.
8. Hudis C, Berry D, Cirrincione C, et al. Five year follow-up of INTC9741: dose-dense (DD) chemotherapy (CRx) is safe and effective. In: SABCS 2005; 2005, Abstr. 41.
9. Sparano JA, Martino S, Jones V, et al.. Phase III study of doxorubicincyclophosphamidefollowed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup trial E1199. In: SABCS 2005; 2005, Abstr. 48.
10. Citron M., Berry D., Cirrincione C., et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21 8 (2003) 1431-1439
11. Eiermann W, Crown J, Chap L, et al. Phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (ACT) in Her-2/neu negative early breast cancer patients with positive axillary lymph nodes: Interim analysis of the BCIRG 005 study. In: SABCS 2005; 2005, Abstr. 1069.
12. Slamon D, Robert N, Pienkowski T, et al. Phase III randomized trialcomparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. In: SABCS 2005; 2005, Abstr. 1.
13. [Abstr 904]. Martin M., Segui M., Antón A., et al. Toxicity and health-related quality of life (HRQoL) in node-negative breast cancer (BC) patients (pts) receiving adjuvant treatment with TAC (docetaxel, doxorubicin, cyclophosphamide) or FAC (5-fluorouracil, doxorubicin, cyclophosphamide): Impact of adding prophylatic growth factors (GF) to TAC. GEICAM Study 9805. Proc Am Soc Clin Oncol 23 Suppl 16 (2005) 29S
14. National Comprehensive Cancer Network (NCCN) guidelines for prophylaxis with myeloid growth factors (2005). http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf
15. van't Veer L., Dai H., van de Vijver M., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 6871 (2002) 530-536
16. van de Vijver M., He Y., van't Veer L., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 25 (2002) 1999-2009
17. Abstr. Sotiriou C., Loi S., Desmedt C., et al. Molecular characterization of clinical grade in breast cancer (BC) challenges the existence of "grade 2" tumors. Proc ASCO 23 16S (2005) 506
18. Rouzier R., Perou C., Symmans W., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11 16 (2005) 5678-5685